The role of soluble TNF p55 and p75 receptors in the development of septic syndrome;Rola rozpuszczalnych receptorów TNF p55 i p75 w rozwoju zespołu septycznego

Polski Merkuriusz Lekarski

Volumn 14, Issue 79, 2003, Pages 69-72

  Modzelewski, Bogdan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cytokine; Sepsis; Soluble receptors of TNF p55 and p75; TNF

Indexed keywords

CELL RECEPTOR; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR;

CYTOKINE RELEASE; CYTOTOXICITY; IMMUNITY; LIGAND BINDING; NONHUMAN; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SEPSIS; SURVIVAL;

ANIMALS; ANTIGENS, CD; CELL MEMBRANE; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0037215083     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Abraham E. i wsp.: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA, 1997 May 21, 277, 19. 1531-8
2. Clark M.A. i wsp.: Effect of a chimeric antibody to tumor necrosis factor -alpha on cytokine and physiologic response in patients with severe sepsis - randomized, clinical trial. Crit. Care Med., 1998, 26, 1650-1659.
3. Comstock K.L. i wsp.: LPS-induced TNF-alpha release from apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J. Mol. Cell. Cardiol., 1998, 30, 2761-2775
4. Doellner-H. i wsp.: Increased serum concentrations of soluble tumor necrosis factor receptors p55 and p75 in early onset neonatal sepsis. Early-Hum-Dev., 1998 Oct, 52, 3, 251-261.
5. Douni-E, i wsp.: A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J. Exp. Med., 1998 Oct 5, 188, 7, 1343-1352.
6. Drost E.M. i wsp.: Increased rigidity and priming of polymorphonuclear leukocytes in sepsis. Am. J. Respir. Crit. Care Med., 1999, 159, 1696-1702.
7. Ebong S.J.: Immunopathologic response to non-lethal sepsis, Shock, 1999, 12, 118-126.
8. Fassbender K. i wsp.: Proinflammatory cytokines: indicators of infection in high-risk patients. J. Lab. Clin. Med., 1997 Nov, 130, 5, 535-539.
9. Holzheimer R.G.: The significance of endotoxin release in experimental and clinical sepsis in surgical patients - evidence for antibiotic-induced endotoxin release? Infection, 1998, 26, 77-84.
10. Hubl W. i wsp.: Differential expression of tumor necrosis factor receptor subtypes on leukocytes in systemic inflammatory response syndrome. Crit. Care Med., 1999, 27, 319-324.
11. Ishikawa K. i wsp.: Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia. J. Trauma., 1998, 44, 1047-1054.
12. Kimura F. i wsp.: Plasma concentration of cytokine antagonists in patients with infection following liver resection. Br. J. Surg., 1998, 85, 1631-1635.
13. Krishnaswamy G. i wsp.: Human endothelium as a source of multifunctional cytokines: molecular regulation and posible role in human disease. J. Interferon. Cytokine. Res., 1999, 19, 91-104.
14. Leon L.R. i wsp.: Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am. J. Physiol., 1998, 275, R269-R277.
15. Lopez-Aguirre Y. i wsp.: Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis. Thromb. Res., 1999, 94, 95-101.
16. Maish G.O. i wsp.: Interleukin-1 receptor antagonist attenuates tumor necrosis factor - induced alterations in wound breaking strength J. Trauma., 1999, 47, 533-537.
17. Martinez M.A. i wsp.: Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor alpha. Crit. Care Med., 1999, 27, 1303-1308.
18. Mercer-Jones M.A. i wsp.: Continuous antibiotic treatment for experimental abdominal sepsis: effects on organ inflammatory cytokine expression and neutrophil sequestration. Br. J. Surg., 1998, 85, 385-389.
19. Messmer U.K. i wsp.: Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells Kidney, Int., 1999, 55, 2322-2327.
20. Modzelewski B. i wsp.: Znaczenie rozpuszczalnego receptora tumor necrosis factor w rozwoju zespołu septycznego. Pol. Przegl. Chir. 1997, 69, 319-324.
21. Modzelewski B.: Release of tumor necrosis factor alpha and its soluble receptor p55 in clinical septic syndrome. Arch. Immunol. Ther. Exp. Warsz., 1997, 45, 213-219.
22. Modzelewski B.: Clinical verification of the value of selected cytokines in the monitoring of the septic syndrome. - Ann Acad. Med. Lodziensis, 1999, 38, 3, 5-23.
23. Oberhoffer M. i wsp.: Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit. Care Med., 1999, 27, 1814-1818.
24. Pinckard K.J. i wsp.: Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J. Immunol., 1997, 157, 3869-3873.
25. Pinsky M.R. i wsp.: Serum cytokine levels in human septic shock. Relation to multiple system organ failure and mortality. Chest, 1998, 163, 565-575.
26. Pittet D. i wsp.: Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am. J. Respir. Crit. Care Med., 1999, 160, 825-827.
27. Sikora J.P.: Rola cytokin i aktywnych form tlenu w patogenezie posocznicy. Pol. Merk. Lek. 2000, 7, 43, 47-50.
28. van der Bruggen T. i wsp.: Lipopolisaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1. MEK1-MEK2. ERK1-ERK2 pathway. Infect. Immun., 1999, 67, 3824-3829.
29. Wakefield C.H. i wsp.: Howie and The Scottish Sepsis intervention group proinflammatory mediator activity, endogenous antagonist and the systemic inflammatory response in intra-abdominal sepsis. Brit. J. Surg., 1998, 85, 818-825.
30. Zhang F.X. i wsp.: Bacterial lipopolysaccharide activates nuclear factor kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and monanuclear phagocytes. J. Biol. Chem., 1999, 274, 7611-7614.